Peng Zhao

Peng Zhao


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2009 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JWJian Wang
Jian Wang
HMHrvoje Miletic
Hrvoje Miletic
PSPer Ø Sakariassen
Per Ø Sakariassen
PHPeter C Huszthy
Peter C Huszthy
HJHege Jacobsen
Hege Jacobsen
PEPer Ø Enger
Per Ø Enger
Establishing clinically relevant animal models of glioblastoma multiforme (GBM) remains a challenge, and many commonly used cell line-based models do not recapitulate the invasive growth patterns of patient GBMs. Previously, we have reported the formation of highly invasive tumour xenografts in nude rats from human GBMs. However, implementing tumour models based on primary tissue requires that these models can be sufficiently standardised with consistently high take rates. In this work, we collected data on growth kinetics from a material of 29 biopsies xenografted in nude rats, and characterised this model with an emphasis on neuropathological and radiological features. The tumour take rate for xenografted GBM biopsies were 96% and remained close to 100% at subsequent passages in vivo, whereas only one of four lower grade tumours engrafted. Average time from transplantation to the onset of symptoms was 125 days ± 11.5 SEM. Histologically, the primary xenografts recapitulated the invasive features of the parent tumours while endothelial cell proliferations and necrosis were mostly absent. After 4-5 in vivo passages, the tumours became more vascular with necrotic areas, but also appeared more circumscribed. MRI typically revealed changes related to tumour growth, several months prior to the onset of symptoms. In vivo passaging of patient GBM biopsies produced tumours representative of the patient tumours, with high take rates and a reproducible disease course. The model provides combinations of angiogenic and invasive phenotypes and represents a good alternative to in vitro propagated cell lines for dissecting mechanisms of brain tumour progression.

19 June 2019 in Oncology Reports
Verified
Journal Article
Open access
PDF file
LMLifeng Miao
Lifeng Miao
ZJZheng Jiang
Zheng Jiang
JWJiwei Wang
Jiwei Wang
NYNing Yang
Ning Yang
QQQichao Qi
Qichao Qi
XLXin-gang Li
Xin-gang Li
Glioblastoma multiforme (GBM) is the most malignant intracranial tumor. Although the affected patients are usually treated with surgery combined with radiotherapy and chemotherapy, the median survival time for GBM patients is still approximately 12‑14 months. Identifying the key molecular mechanisms and targets of GBM development may therefore lead to the development of improved therapies for GBM patients. In the present study, the clinical significance and potential function of epithelial membrane protein 1 (EMP1) in malignant gliomas were investigated. Increased EMP1 expression was associated with increasing tumor grade (P<0.001) and worse prognosis in patients (P<0.001) based on TCGA, Rembrandt and CGGA databases for human gliomas. In vitro, gene silencing of EMP1 in U87MG and P3 GBM (primary glioma) cells significantly inhibited tumor proliferation and invasion. In addition, it was revealed that activation of the PI3K/AKT/mTOR signaling pathway is the driving force of EMP1‑promoted glioma progression. Finally, it was demonstrated, using an intracranial GBM animal model, that EMP1 knockdown significantly inhibits tumor growth in vivo and increases overall survival in tumor‑bearing animals. Our research provides new insights into the molecular mechanisms underlying EMP1 knockdown‑mediated inhibition of GBM cell invasion and raises the possibility that targeting of EMP1 may represent a promising strategy for the treatment of GBM.

21 February 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
YXYangyang Xu
Yangyang Xu
LZLin Zhang
Lin Zhang
YWYuzhen Wei
Yuzhen Wei
XZXin Zhang
Xin Zhang
RXRan Xu
Ran Xu
XLXin-gang Li
Xin-gang Li
Procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 promotes hypoxia-induced glioma migration and invasion


11 September 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
TSTao Sun
Tao Sun
YWYanzhao Wu
Yanzhao Wu
GLGuohao Liu
Guohao Liu
ZXZhiwei Xue
Zhiwei Xue
MYMengchen Yu
Mengchen Yu
DWDonghai Wang
Donghai Wang
Background: The link between lymph node (LN) function and atherosclerosis is unclear, especially at the single‐cell level. This study explores the relationship between pericarotid LNs and plaque stability using single‐cell transcriptome analysis. Methods: We enrolled 106 patients with severe internal carotid artery stenosis undergoing carotid endarterectomy. We recorded baseline clinical data and pericarotid LN size, and analyzed plaque composition to assess its association with enlarged LNs. Single‐cell transcriptome and T/B‐cell receptor sequencing were used to profile pericarotid LNs. Results: Patients with symptomatic carotid atherosclerosis had more enlarged pericarotid LNs ( P <0.001), indicating plaque instability. This was characterized by increased inflammation, greater CD68 + macrophage infiltration ( P <0.001), and reduced fibrous content ( P <0.001). Single‐cell analysis identified 3 main cellular compartments: lymphocytes, myeloid cells, and stromal cells. Enlarged LNs had significantly more naive B and T cells ( P <0.001), suggesting heightened immune response. Macrophages and neutrophils may help in cholesterol transport and degradation, while stromal cells may regulate the immune microenvironment by influencing T‐cell tolerance and lymphocyte trafficking. Conclusions: Enlarged pericarotid LNs are potential biomarkers for plaque instability and recent ischemic events. This study provides a comprehensive single‐cell transcriptomic landscape of human LNs in atherosclerosis.

5 September 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
XYXiaobing Yang
Xiaobing Yang
DLDi Lu
Di Lu
YSYanfei Sun
Yanfei Sun
TWTiandi Wei
Tiandi Wei
DMDulegeqi Man
Dulegeqi Man
XLXin-gang Li
Xin-gang Li
Introduction: Safranal is an active component of the traditional Tibetan medicine (TTM) saffron, which has potential anticancer activity.Methods and results: Here, we studied the therapeutic effect and mechanism of safranal on GBM. CCK-8, GBM-brain organoid coculture experiments and 3D tumour spheroid invasion assays showed that safranal inhibited GBM cell proliferation and invasion in vitro. Network pharmacology, RNA-seq, molecular docking analysis, western blotting, apoptosis, and cell cycle assays predicted and verified that safranal could promote GBM cell apoptosis and G2/M phase arrest and inhibit the PI3K/AKT/mTOR axis. In vivo experiments showed that safranal could inhibit GBM cell growth alone and in combination with TMZ.Conclusion: This study revealed that safranal inhibits GBM cell growth in vivo and in vitro, promotes GBM cell apoptosis and G2/M phase arrest, inhibits the PI3K/AKT/mTOR axis and cooperate with TMZ.